Dapagliflozin for Prediabetes and Lifestyle Changes

Inclusion criteria: 1. Male, female or intersexualpatients aged between 35 and 75 years (including) 2. Prediabetes (defined by one of the following: FG ≥ 100 mg/dL or 2h OGTT glucose ≥ 140 mg/dL) 3. BMI ≥20 kg/m2 4. TSH within normal range 5. Ability to understand and follow study-related instructions 6. Negative pregnancy test for premenopausal women (blood) 7. Patients who are receiving thyroid replacement therapy must be on a stable treatment regimen for at least 3 months prior to the screening visit (V-1) 8. Patients who are receiving antihypertensive medication such as mineralocorticoid receptor antagonists must be on a stable treatment regimen for at least 6 weeks prior to the screening visit (V-1) 9. Patients who are treated antihypertensive medication such as ACE inhibitors and AT1receptor antagonists, thiazides as well as loop diuretics must be on stable treatment for at least 2 weeks 10. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. 11. Patients will not be included in the study if, in the opinion of the investigator participation will lead to an unacceptable risk to the subjects' safety or well-being Exclusion Criteria 1. Manifest diabetes mellitus 2. eGFR (as calculated by the CKD-EPI equation) \< 60 ml/min/1.73 m2 3. all glucose altering medications (including current therapy with dapagliflozin or empagliflozin or any other SGLT2-Inhibitor) 4. Symptomatic chronic congestive heart disease 5. New diuretic or antihypertensive medication or dosing changes within the last 2 weeks, for aldosterone antagonists within the last 6 weeks 6. known or suspected orthostatic proteinuria 7. any acute severe or chronic severe illness, including the following: malignant disease ongoing or \< 5 years ago, unstable cardiovascular disease or procedure within 3 months prior to enrolment or expected to require coronary revascularisation procedure 8. history of or current therapy for congestive heart failure (NYHA III and IV), pacemaker or aortic stenosis \> II° 9. acute pancreatic disease (i.e. elevated lipase 3x ULN) 10. rapidly progressing renal disease or anuria 11. known HIV infection or positive HIV test at screening 12. history of or planned organ transplantation 13. history or presence of inflammatory bowel disease or other severe gastrointestinal diseases, particularly those which may impact gastric emptying, such as gastroparesis or pyloric stenosis 14. relevant hepatic disease, including, but not limited to, acute hepatitis, chronic active hepatitis, or severe hepatic insufficiency, including patients with alanine aminotransferase and/or aspartate aminotransferase \> 3 x upper limit of normal and/or total bilirubin (TB) \> 2 mg/dL (\> 34.2 μmol/L) (patients with TB \> 2 mg/dL \[\> 34.2 μmol/L\] and documented Gilbert's syndrome will be allowed to participate). 15. treatment with glucocorticoids 16. antibiotic treatment within the last 4 weeks 17. History of ketoacidosis 18. history of repeated urogenital infection 19. hemoglobinopathies, haemolytic anaemia, or chronic anaemia (haemoglobin concentration \<12.0 g/dL) 20. presence of psychiatric disorder or new intake of antidepressant or antipsychotic agents(start within last 3 months) 21. Positive Screening for a severe depression (BDI ≥29) 22. history of hypersensitivity to the study drug or its ingredients 23. more than 5% weight loss in the last 3 months 24. Pregnant or breastfeeding women 25. Subject (male, female or intersexual) is not willing to use highly effective contraceptive methods during treatment and for 14 days (male or female) after the end of treatment (highly effective methods are defined as: combined hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, sexual abstinence). Vasectomized partner is a highly effective birth control method provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success. 26. Current participation in other interventional clinical trials or treatment with other IMPs within five times the half-life of the drug 27. Previous therapy with dapagliflozin or other drugs that can potentially lead to overlapping toxicities within five times the half-life of the drug 28. Patients who do not want to be informed about accidental findings 29. Any other clinical condition that would jeopardize subjects' safety or well-being while participating in this clinical trial 30. Patients will not be included in the study if, in the opinion of the investigator, participation leads to an unacceptable risk to their safety and well-being